In April, Mumbai-based pharmaceutical company Wockhardt announced it had received five marketing approvals for its generic medicines, versions of those that have gone off patents, from the US Food and Drug Administration in five weeks.
Ranbaxy earned $114 million from its US operations in 2006. It launched 10 new products during the year. The company said that the revenues from the sale of the newly acquired brands would be reflected from the next quarter.
Shivinder's dream project, of course, is the Medicity he wants to put up at Gurgaon on the outskirts of New Delhi. That is where the problem with Trehan began, who has his own plans to come up with a similar project at Gurgaon.
Following hectic negotiations, Fortis Healthcare managing director Shivinder Singh and Naresh Trehan have finally smoked the peace pipe
After making big-ticket acquisitions abroad, leading Indian pharmaceutical companies like Dr Reddy's Laboratories, Ranbaxy Laboratories, and Aurobindo Pharma are rapidly shifting production to their Indian facilities.
With India slowly but steadily morphing into a global pharmaceutical R&D hub, scientists have run into short supply.
The changes would be immediately effective in countries like Columbia, South Korea, Peru and Panama, where FTAs are in the final stages of approval.
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
Ranbaxy Laboratories, the country's biggest drugmaker, is all set to focus its energies in developing and marketing niche products where price erosion is minimal
The pace of privatisation of the Indian healthcare segment is expected to be the fastest in the coming years.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
Data from the Central Information Commission, the apex body that hears complaints regarding denial of information under RTI, shows that corporate houses are increasingly using RTI to extract information from public authorities.
Pfizer's blockbuster drug Viagra (sildenafil citrate), hitherto approved for use in treatment of erectile dysfunction, may soon acquire a new identity as a "life saving drug" in treating pulmonary arterial hypertension in children.
The venue of the battle by Swiss multinational Novartis AG against the rejection of its patent application for blockbuster cancer drug Gleevac will now shift to the Patent Appellate Board's office.
Australia has joined the UK, USA and Canada in warning its citizens against using unapproved traditional medicines from India and China.
Hetero is the only Indian partner of multinational drug major Roche Scientific for the manufacture and supply of the latter's patented drug, Tamilflu in developing countries.
Merck is all set to introduce three of its money-spinning drugs - Cosopt, Invanz and Pneuvax in India.
Pharmaceutical companies which increase prices of their medicines beyond 10 per cent in a year will face regulatory action.
The resultant price increase was the cause of a surprise upward variation in the "drug and medicines" segment of the weekly wholesale price index of the ministry of commerce and Industry last week, it is learnt.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances